Moderna and Merck Revive mRNA Hopes With Melanoma Trial Success
Moderna and Merck announced that their experimental personalized mRNA cancer vaccine, intismeran, combined with Keytruda, successfully met its primary endpoints in a Phase 3 trial for high-risk melanoma.
